Search Results - "Shaw, Reid"

Personalized In Vitro and In Vivo Cancer Models to Guide Precision Medicine by Pauli, Chantal, Hopkins, Benjamin D, Prandi, Davide, Shaw, Reid, Fedrizzi, Tarcisio, Sboner, Andrea, Sailer, Verena, Augello, Michael, Puca, Loredana, Rosati, Rachele, McNary, Terra J, Churakova, Yelena, Cheung, Cynthia, Triscott, Joanna, Pisapia, David, Rao, Rema, Mosquera, Juan Miguel, Robinson, Brian, Faltas, Bishoy M, Emerling, Brooke E, Gadi, Vijayakrishna K, Bernard, Brady, Elemento, Olivier, Beltran, Himisha, Demichelis, Francesca, Kemp, Christopher J, Grandori, Carla, Cantley, Lewis C, Rubin, Mark A

“…Precision medicine is an approach that takes into account the influence of individuals' genes, environment, and lifestyle exposures to tailor interventions…”
Get more information

Patient derived organoids to model rare prostate cancer phenotypes by Puca, Loredana, Bareja, Rohan, Prandi, Davide, Shaw, Reid, Benelli, Matteo, Karthaus, Wouter R., Hess, Judy, Sigouros, Michael, Donoghue, Adam, Kossai, Myriam, Gao, Dong, Cyrta, Joanna, Sailer, Verena, Vosoughi, Aram, Pauli, Chantal, Churakova, Yelena, Cheung, Cynthia, Deonarine, Lesa Dayal, McNary, Terra J., Rosati, Rachele, Tagawa, Scott T., Nanus, David M., Mosquera, Juan Miguel, Sawyers, Charles L., Chen, Yu, Inghirami, Giorgio, Rao, Rema A., Grandori, Carla, Elemento, Olivier, Sboner, Andrea, Demichelis, Francesca, Rubin, Mark A., Beltran, Himisha

“…A major hurdle in the study of rare tumors is a lack of existing preclinical models. Neuroendocrine prostate cancer is an uncommon and aggressive histologic…”
Get full text

A Functional Precision Oncology Approach to Identify Treatment Strategies for Myxofibrosarcoma Patients by Pauli, Chantal, De Boni, Lamberto, Pauwels, Jonathan E, Chen, Yanjiang, Planas-Paz, Lara, Shaw, Reid, Emerling, Brooke M, Grandori, Carla, Hopkins, Benjamin D, Rubin, Mark A

“…In this era of precision medicine, numerous workflows for the targeting of high-recurrent mutations in common tumor types have been developed, leaving patients…”
Get full text

Clinical considerations at the intersection of hematopoietic cell transplantation and hereditary hematopoietic malignancy by O'Connor, Timothy E, Shaw, Reid, Madero-Marroquin, Rafael, Roloff, Gregory W

“…In recent years, advances in genetics and the integration of clinical-grade next-generation sequencing (NGS) assays into patient care have facilitated broader…”
Get full text

Inhibition of HIV-1 Ribonuclease H by a Novel Diketo Acid, 4-[5-(Benzoylamino)thien-2-yl]-2,4-dioxobutanoic Acid by Shaw-Reid, Cathryn A, Munshi, Vandna, Graham, Pia, Wolfe, Abigail, Witmer, Marc, Danzeisen, Renee, Olsen, David B, Carroll, Steven S, Embrey, Mark, Wai, John S, Miller, Michael D, Cole, James L, Hazuda, Daria J

“…Human immunodeficiency virus-type 1 (HIV-1) reverse transcriptase (RT) coordinates DNA polymerization and ribonuclease H (RNase H) activities using two…”
Get full text

Multicenter analysis of immunosuppressive medications on the risk of malignancy following adult solid organ transplantation by Shaw, Reid, Haque, Ali R, Luu, Tyler, O'Connor, Timothy E, Hamidi, Adam, Fitzsimons, Jack, Varda, Bianca, Kwon, Danny, Whitcomb, Cody, Gregorowicz, Alex, Roloff, Gregory W, Bemiss, Bradford C, Kallwitz, Eric R, Hagen, Patrick A, Berg, Stephanie

“…This study aimed to assess the risk of maintenance immunosuppression on the post-transplant risk of malignancy across all solid organ transplant types. This is…”
Get full text

BET, SRC, and BCL2 family inhibitors are synergistic drug combinations with PARP inhibitors in ovarian cancer by Lui, Goldie Y.L., Shaw, Reid, Schaub, Franz X., Stork, Isabella N., Gurley, Kay E., Bridgwater, Caroline, Diaz, Robert L., Rosati, Rachele, Swan, Hallie A., Ince, Tan A., Harding, Thomas C., Gadi, Vijayakrishna K., Goff, Barbara A., Kemp, Christopher J., Swisher, Elizabeth M., Grandori, Carla

“…Homologous recombination deficiencies (HRD) are present in approximately half of epithelial ovarian cancers, for which PARP inhibitors (PARPi) are becoming a…”
Get full text

Dissecting the Effects of DNA Polymerase and Ribonuclease H Inhibitor Combinations on HIV-1 Reverse-Transcriptase Activities by Shaw-Reid, Cathryn A, Feuston, Bradley, Munshi, Vandna, Getty, Krista, Krueger, Julie, Hazuda, Daria J, Parniak, Michael A, Miller, Michael D, Lewis, Dale

“…Although HIV-1 reverse transcriptase (RT) DNA polymerase and ribonuclease H (RNase H) activities reside in spatially distinct domains of the enzyme, inhibitors…”
Get full text

The EntF and EntE Adenylation Domains of Escherichia coli Enterobactin Synthetase: Sequestration and Selectivity in acyl-AMP Transfers to Thiolation Domain Cosubstrates by Ehmann, David E, Shaw-Reid, Cathryn A, Losey, Heather C, Walsh, Christopher T

“…Enterobactin, the tris-(N-(2,3-dihydroxybenzoyl)serine) trilactone siderophore of Escherichia coli, is synthesized by a three-protein (EntE, B, F) six-module…”
Get full text

Elucidation of anaplerotic pathways in Corynebacterium glutamicum via [sup.13]C-NMR spectroscopy and GC-MS by Park, S.M, Shaw-Reid, C, Sinskey, A.J, Stephanopoulos, G

Get full text

Flux through the tetrahydrodipicolinate succinylase pathway is dispensable for L-lysine production in Corynebacterium glutamicum by SHAW-REID, C. A, MCCORMICK, M. M, SINSKEY, A. J, STEPHANOPOULOS, G

“…The N-succinyl-LL-diaminopimelate desuccinylase gene (dapE) in the four-step succinylase branch of the L-lysine biosynthetic pathway of Corynebacterium…”
Get full text

Stagnation in Quality of Next-Generation Sequencing Assays for the Diagnosis of Hereditary Hematopoietic Malignancies by Roloff, Gregory W., Shaw, Reid, O'Connor, Timothy E., Drazer, Michael W.

Get full text

Clinical guideline variability in the diagnosis of hereditary hematopoietic malignancy syndromes by Hamidi, Adam, Roloff, Gregory W., Shaw, Reid, Acevedo, Maria, Smith, Shaili, Drazer, Michael W.

“…A growing understanding of the complexities of hematopoietic malignancies necessitates the existence of clinical recommendations that are sufficiently…”
Get full text

Abstract NT-108: TARGETING BROMODOMAIN PROTEINS AS A THERAPEUTIC STRATEGY FOR CLEAR CELL CARCINOMA OF THE OVARY by Shigeta, Shogo, Shaw, Reid, Moser, Russell, Gurley, Kay, Lui, Goldie, Grandori, Carla, Kemp, Christopher

“…Abstract Background and Objectives: Clear cell carcinoma of the ovary (OCCC) is more resistant to platinum-based chemotherapy than high-grade serous ovarian…”
Get full text

S2661 Verrucous Esophageal Carcinoma: A Rare Cause of Dysphagia by Varda, Bianca, Hong, Paul, Alur, Abhishek, Shaw, Reid, Hoilat, Judie, Regmi, Aayushma, Wakade, Zuie, Sargon, Peter, Haseeb, Abdul

Get full text

Species selection tool: Soil‐specific forage species selection for New York State by Post, Christopher, Cherney, Jerome, Reid, Shaw

“…Selection of forage species that are best suited to a particular soil type and forage use provide the most efficient land use. This program was developed to…”
Get full text

Assessing the Predictive Value of Methicillin-Resistant Staphylococcus aureus Nares Colonization Among Transplant Recipients and Patients With Neutropenia by Shaw, Reid, Zander, Alison, Ronnie, Tanisha, Azari, Zubeen, Gregorowicz, Alex, Albarillo, Fritzie

“…Abstract Background Methicillin-resistant Staphylococcus aureus (MRSA) nares screening has been shown to be a powerful antibiotic stewardship tool for MRSA…”
Get full text

Targeting BET Proteins BRD2 and BRD3 in Combination with PI3K-AKT Inhibition as a Therapeutic Strategy for Ovarian Clear Cell Carcinoma by Shigeta, Shogo, Lui, Goldie Y L, Shaw, Reid, Moser, Russell, Gurley, Kay E, Durenberger, Grace, Rosati, Rachele, Diaz, Robert L, Ince, Tan A, Swisher, Elizabeth M, Grandori, Carla, Kemp, Christopher J

“…Ovarian clear cell carcinoma (OCCC) is a rare, chemo-resistant subtype of ovarian cancer. To identify novel therapeutic targets and combination therapies for…”
Get full text

Stagnation in quality of next‐generation sequencing assays for the diagnosis of hereditary hematopoietic malignancies by Roloff, Gregory W., Shaw, Reid, O'Connor, Timothy E., Hathaway, Feighanne, Drazer, Michael W.

“…Hereditary hematopoietic malignancies (HHMs) are inherited syndromes that confer the risk of blood cancer development. With the rapid acceleration of…”
Get full text

Abstract GMM-051: A CLIA-CERTIFIED HIGH-THROUGHPUT DRUG SCREENING PLATFORM FOR OVARIAN CANCER TO INFORM PERSONALIZED CANCER CARE AND DISCOVER NOVEL COMBINATIONS by Schaub, Franz X, Maisel, Sabrina, Shaw, Reid, Rosati, Rachele, Bridgwater, Caroline, Churchill, Michael, Diaz, Robert, Murphy, Stephanie Tatem, Pereira, Shalini, Kemp, Christopher, Gadi, VK, Grandori, Carla

“…Abstract BACKGROUND: Metastatic disease in ovarian cancer is difficult to treat and patients often exhaust standard-of-care regimens. To gain a better…”
Get full text